Absence of HIV-1 shedding in male genital tract after 1 year of first-line lopinavir/ritonavir alone or in combination with zidovudine/ lamivudine

Journal of Antimicrobial Chemotherapy

Volumn 61, Issue 6, 2008, Pages 1344-1347

  Ghosn, Jade ^a,b   Chaix, Marie Laure ^a   Peytavin, Gilles ^c   Bresson, Jean Louis ^d   Galimand, Julie ^a   Girard, Pierre Marie ^e   Raffi, François ^f   Cohen Codar, Isabelle ^g   Delfraissy, Jean François ^b   Rouzioux, Christine ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b BICÊTRE HOSPITAL   (France)

^c BICHAT HOSPITAL   (France)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

^e HÔPITAL SAINT ANTOINE   (France)

^f HÔTEL DIEU   (France)

^g Abbott   (France)

Author keywords

Compartmentalization; Protease inhibitor; Sanctuary site; Semen

Indexed keywords

LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; VIRUS RNA;

ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG SEMEN LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MALE; MALE GENITAL SYSTEM; MONOTHERAPY; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; SEMEN ANALYSIS; TREATMENT OUTCOME; VIRUS LOAD; VIRUS SHEDDING;

ANTI-HIV AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG THERAPY, COMBINATION; GENITALIA, MALE; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; LONGITUDINAL STUDIES; MALE; PLASMA; PYRIMIDINONES; RITONAVIR; RNA, VIRAL; SEMEN; TIME FACTORS; VIRUS SHEDDING; ZIDOVUDINE;

EID: 44449118908     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn098     Document Type: Article

References (10)

1. Swindells S, DiRienzo AG, Wilkin T et al. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression. JAMA 2006, 296: 806-14.
2. Vernazza P, Daneel S, Schiffer V et al. The role of a compartment penetration in Pl-monotnerapy: The atazanavir-ritonavir monomaintance (ATARITMO) trial. AIDS 2007; 21: 1309-15.
3. Delfraissy J, Flandre P, Delaugerre C et al. Liponavir/ritonavir monotherapy or plus zidovudine nnd lamivudine in antiretroval naïve HIV-infected patients. AIDS 2008; 22: 385-93.
4. Taylor S, Pereira AS. Antiretroviral drug concentrations in semen of HIV-1 infected men. Sex Transm Infect 2001; 77: 4-11.
5. Ghosn J, Chaix ML, Peytavin G et al. Penetration of enfuvirtide, tenofovir, efavirenz, and protease inhibitors in the genital tract of HIV-1-infected men. AIDS 2004; 18: 1958-61.
6. La Sala GB, Pilotti, E, Nicoli A et al. Dynamics of HIV viral load in blood and semen of patients under HAART: Impact of therapy in assisted reproduction procedures. AIDS 2007; 21: 377-9.
7. Ghosn J, Viard JP, Katlama C et al. Evidence of genotypic resistance diversity of archived and circulating viral strains in blood and semen of pre-treated HIV-infected men. AIDS 2004; 18: 447-57.
8. Marcelin AG, Cohen-Codar I, King MS et al. Virology and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patients. Antimicrob Agents Chemother 2005; 49: 1720-6.
9. Isaac A, Taylor S, Cane P et al. Lopinavir/ritonavir combined with twice-daily 400 mg indinavir: Pharmacokinetics and pharmacodynamics in blood, CSF and semen. J Antimicrob Chemother 2004; 54: 498-502.
10. Tachet A, Dulioust E, Salmon D et al. Detection and quantification of HIV-1 in semen: Identification of a subpopulation of men at high potential risk of viral sexual transmission. AIDS 1999; 13: 823-31.